Iqvia inks genomics deal to advance discovery of precision meds
As per the agreement, Genomics England’s patient-consented, de-identified datasets will be incorporated into Iqvia’s E360 analytics platform for use by authorised researchers.
Genomics England was set up by the Department of Health and Social Care to deliver the 100,000 Genomes Project – a project designed to sequence whole genomes from national health system (NHS) patients and their families.
According to Iqvia, connecting clinical-genomic datasets will enable drugmakers and researchers to run association studies of genomics and observable traits, safety trials, and burden-of-illness, as well as discovery analytics.
“Our collaboration advances the analysis of these complex datasets, which could accelerate the discovery of precision therapies, [and] improve access and health outcomes,” said Iqvia’s president of real-world and analytics solutions, Jon Resnick.
“Drawing insights from clinical-genomics datasets is the future of real-world research,” he added.
The alliance marks Iqvia’s latest investment in the clinical research space, following the firm’s launch of a virtual, patient-centric Study Hub in June this year, and plans to expand an alliance with Salesforce to release automated clinical trial processes.
